Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology

The Eastern Cooperative Oncology Group experience

Elisabeth M. Paietta, Janis Racevskis, J. M. Bennett, D. Neuberg, P. A. Cassileth, J. M. Rowe, P. H. Wiernik

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Evaluable karyotypes were available in 776 of 1148 adult patients who were entered on acute myeloid leukemia (AML) treatment protocols of the Eastern Cooperative Oncology Group. Among these, we found seven patients (0.9%) with t(9;22)(q34;q11), the Philadelphia (Ph) chromosome, in bone marrow metaphases. All fulfilled the FAB criteria for AML (three M0, two M1, two M2), although one patient presented with an additional, distinct lymphoid blast cell population. Chromosomal aberrations in addition to the Ph chromosome were seen in four patients (including two cases of monosomy 7). Molecular analysis by polymerase chain reaction in four patients tested revealed variable BCR/ABL transcript forms (ela2, b2a2, b3a2, b2a3+e1a2). By immunophenotyping, all seven patients were myeloid based on the overall antigen expression pattern. However, all but one demonstrated lymphoid associated antigens on the myeloid blast cells. The six evaluable patients failed to respond to treatment with a standard anthracycline/cytosine arabinoside-containing regimen. We conclude that the incidence of the Ph chromosome in AML is very low. Although both genotypically and phenotypically heterogenous, Ph chromosome-positive AML, represents a clinically distinct entity with poor outcome.

Original languageEnglish (US)
Pages (from-to)1881-1885
Number of pages5
JournalLeukemia
Volume12
Issue number12
StatePublished - 1998

Fingerprint

Philadelphia Chromosome
Acute Myeloid Leukemia
Antigens
Immunophenotyping
Anthracyclines
Cytarabine
Myeloid Cells
Metaphase
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical Protocols
Karyotype
Chromosome Aberrations
Bone Marrow
Lymphocytes
Polymerase Chain Reaction
Incidence
Population

Keywords

  • Acute leukemia
  • FAB
  • Immunophenotype
  • Myeloid
  • Philadelphia chromosome

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology : The Eastern Cooperative Oncology Group experience. / Paietta, Elisabeth M.; Racevskis, Janis; Bennett, J. M.; Neuberg, D.; Cassileth, P. A.; Rowe, J. M.; Wiernik, P. H.

In: Leukemia, Vol. 12, No. 12, 1998, p. 1881-1885.

Research output: Contribution to journalArticle

@article{d68aaa3fe01249b883e930e64d3c8025,
title = "Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: The Eastern Cooperative Oncology Group experience",
abstract = "Evaluable karyotypes were available in 776 of 1148 adult patients who were entered on acute myeloid leukemia (AML) treatment protocols of the Eastern Cooperative Oncology Group. Among these, we found seven patients (0.9{\%}) with t(9;22)(q34;q11), the Philadelphia (Ph) chromosome, in bone marrow metaphases. All fulfilled the FAB criteria for AML (three M0, two M1, two M2), although one patient presented with an additional, distinct lymphoid blast cell population. Chromosomal aberrations in addition to the Ph chromosome were seen in four patients (including two cases of monosomy 7). Molecular analysis by polymerase chain reaction in four patients tested revealed variable BCR/ABL transcript forms (ela2, b2a2, b3a2, b2a3+e1a2). By immunophenotyping, all seven patients were myeloid based on the overall antigen expression pattern. However, all but one demonstrated lymphoid associated antigens on the myeloid blast cells. The six evaluable patients failed to respond to treatment with a standard anthracycline/cytosine arabinoside-containing regimen. We conclude that the incidence of the Ph chromosome in AML is very low. Although both genotypically and phenotypically heterogenous, Ph chromosome-positive AML, represents a clinically distinct entity with poor outcome.",
keywords = "Acute leukemia, FAB, Immunophenotype, Myeloid, Philadelphia chromosome",
author = "Paietta, {Elisabeth M.} and Janis Racevskis and Bennett, {J. M.} and D. Neuberg and Cassileth, {P. A.} and Rowe, {J. M.} and Wiernik, {P. H.}",
year = "1998",
language = "English (US)",
volume = "12",
pages = "1881--1885",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology

T2 - The Eastern Cooperative Oncology Group experience

AU - Paietta, Elisabeth M.

AU - Racevskis, Janis

AU - Bennett, J. M.

AU - Neuberg, D.

AU - Cassileth, P. A.

AU - Rowe, J. M.

AU - Wiernik, P. H.

PY - 1998

Y1 - 1998

N2 - Evaluable karyotypes were available in 776 of 1148 adult patients who were entered on acute myeloid leukemia (AML) treatment protocols of the Eastern Cooperative Oncology Group. Among these, we found seven patients (0.9%) with t(9;22)(q34;q11), the Philadelphia (Ph) chromosome, in bone marrow metaphases. All fulfilled the FAB criteria for AML (three M0, two M1, two M2), although one patient presented with an additional, distinct lymphoid blast cell population. Chromosomal aberrations in addition to the Ph chromosome were seen in four patients (including two cases of monosomy 7). Molecular analysis by polymerase chain reaction in four patients tested revealed variable BCR/ABL transcript forms (ela2, b2a2, b3a2, b2a3+e1a2). By immunophenotyping, all seven patients were myeloid based on the overall antigen expression pattern. However, all but one demonstrated lymphoid associated antigens on the myeloid blast cells. The six evaluable patients failed to respond to treatment with a standard anthracycline/cytosine arabinoside-containing regimen. We conclude that the incidence of the Ph chromosome in AML is very low. Although both genotypically and phenotypically heterogenous, Ph chromosome-positive AML, represents a clinically distinct entity with poor outcome.

AB - Evaluable karyotypes were available in 776 of 1148 adult patients who were entered on acute myeloid leukemia (AML) treatment protocols of the Eastern Cooperative Oncology Group. Among these, we found seven patients (0.9%) with t(9;22)(q34;q11), the Philadelphia (Ph) chromosome, in bone marrow metaphases. All fulfilled the FAB criteria for AML (three M0, two M1, two M2), although one patient presented with an additional, distinct lymphoid blast cell population. Chromosomal aberrations in addition to the Ph chromosome were seen in four patients (including two cases of monosomy 7). Molecular analysis by polymerase chain reaction in four patients tested revealed variable BCR/ABL transcript forms (ela2, b2a2, b3a2, b2a3+e1a2). By immunophenotyping, all seven patients were myeloid based on the overall antigen expression pattern. However, all but one demonstrated lymphoid associated antigens on the myeloid blast cells. The six evaluable patients failed to respond to treatment with a standard anthracycline/cytosine arabinoside-containing regimen. We conclude that the incidence of the Ph chromosome in AML is very low. Although both genotypically and phenotypically heterogenous, Ph chromosome-positive AML, represents a clinically distinct entity with poor outcome.

KW - Acute leukemia

KW - FAB

KW - Immunophenotype

KW - Myeloid

KW - Philadelphia chromosome

UR - http://www.scopus.com/inward/record.url?scp=0031730466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031730466&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 1881

EP - 1885

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 12

ER -